Satellite Symposia
Sunday, 2 June 2019
| Satellite Symposium (SAT) Uriach 17:30 – 19:00, Hall 8 |
 |
Itching for expert insights? Interactive clinical cases to better manage your pruritus and urticaria patients.
Chair: Marcus Maurer, Germany
Introduction and welcome
Speaker: Marcus Maurer, Germany
Introduction to urticaria (CSU) and skin pruritus
Speaker: Marcus Maurer, Germany
Patients itching for relief
Speaker: Ana Giménez-Arnau, Spain
Speaker: Montserrat Álvaro, Spain
Speaker: Zuotao Zhao, China
Panel discussion/ debate
Speaker: Marcus Maurer, Germany
| Satellite Symposium (SAT) Mylan 17:30 – 19:00, Hall 10 |
 |
New Data on Adrenalin Delivery: Dismantling Believes in the Treatment of Anaphylaxis
Chair: Margitta Worm, Germany
Chair: Motohiro Ebisawa, Japan
Introduction
Speaker: Margitta Worm, Germany
Adrenalin Delivery: new data
Speaker: Ferdinand Kopietz, Germany
Does Epipen fit to all anaphylactic patients?
Speaker: George du Toit, United Kingdom
Need for 2 AAIs – Unaccomplished EMA recommendation
Speaker: Antonella Muraro, Italy
Conclusion
Speaker: Motohiro Ebisawa, Japan
Q&A session – All
| Satellite Symposium (SAT) Takeda Pharmaceuticals 17:30 – 19:00, Hall 9 |
Lanadelumab, a First-of-Its-Kind Prevention Treatment in Hereditary Angiodema (HAE)
Learning objectives: Leading international HAE experts will lead a symposium to review the clinical data for lanadelumab*, which was approved by the European Commission in 2018. The audience will learn about the burden and unpredictability of the disease and the opportunity to redefine HAE prevention with lanadelumab. The speakers will present the clinical efficacy data, dosing and safety profile, as observed in the phase 3 HELP study. The symposium will incorporate both real-world experiences and supporting clinical data to introduce lanadelumab as a first-of-its-kind preventive treatment for HAE.
*lanadelumab is a fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Introductions
Understanding the Burden of HAE
Speaker: Markus Magerl, Germany
Clinical Data from the HELP Study
Speaker: Aleena Banerji, United States
Beyond the Data: Key Features of Lanadelumab
Speaker: Markus Magerl, Germany
Q & A – Moderator and Speakers
| Satellite Symposium (SAT) GSK 17:30 – 19:00, Hall 3 |
Chair: André Moreira, Portugal
Welcome & Chairman’s introduction
Speaker: André Moreira, Portugal
Different MoA translates in different efficacy
Speaker: Ana Todo-Bom, Portugal
Mepolizumab: The evidence of lasting efficacy & safety to support clinician’s choice
Speaker: Emilio Pizzichini, Brazil
Clinician’s perspectives: The long-term experience with Mepolizumab
Speaker: Stefan Cimbollek, Spain
Q & A – Close remarks
Speaker: Manuel Branco Ferreira, Portugal
| Satellite Symposium (SAT) FAES FARMA and Menarini Group 17:30 – 19:00, Hall 5 |
Bilastine: a lifetime companion – Value every moment of your life
Chair: Martin Church, United Kingdom
Patients and their Rhinitis-treatment – an on-off-Relationship
Speaker: Ralph Mösges, Germany
Unmet needs in Urticaria – Zeroing-In on the right Treatment
Speaker: Marysia Recto, The Philippines
Preserve children’s daily-life activities – to be on the safe side
Speaker: Zoltán Nóvak, Hungary
| Satellite Symposium (SAT) Integritas Communications 17:30 – 19:00, Hall 7 |
Looking ahead: Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis
Chair: Mark Boguniewicz, United States
Introduction and Preassessment
Speaker: Mark Boguniewicz, United States
Atopic Dermatitis: Mechanistic Rationales for Advances in Therapy
Speaker: Michael Ardern-Jones, United Kingdom
Comprehensive Patient Evaluations: From Triggers to Comorbidities
Speaker: Mark Boguniewicz, United States
Long-term Management Strategies for Moderate-to-Severe Disease
Speaker: Marjolein Saskia de Bruin-Weller, Netherlands
Postactivity Questionnaire and Question & Answer Session
Speaker: Mark Boguniewicz, United States
Monday, 3 June 2019
| Satellite Symposium (SAT) Laboratorios LETI 17:45 – 19:15, Hall 8 |
 |
New challenges in allergic diseases and improved technology to better control safety and efficacy of personalized immunotherapy
Chair: Torsten Zuberbier, Germany
How and why prevalence and diversity of allergies has increased and will further increase both in the next decade.
Speaker: Javier Domínguez, Spain
LETI’s safety and efficacy evidence map.
Speaker: Ludger Klimek, Germany
Are we ready to take advantage of digital transformation to help allergic patients?
Speaker: Ignacio Hernández Medrano, Spain
Increasing precision of personalized allergen immunotherapy through R&D.
Speaker: Mohamed Shamji, United Kingdom
| Satellite Symposium (SAT) Sanofi Genzyme and Regeneron 17:45 – 19:15, Hall 3 |
 |
A New Era in the Management of Type 2 Inflammatory Diseases: Asthma, CRSwNP, and Atopic Dermatitis — New Insights, New Treatment Options
Learning objectives:
This interactive symposium will explore how type 2 inflammation underpins multiple chronic inflammatory diseases of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis, while considering the high disease burden and unmet medical needs associated with these diseases. The latest clinical data on biologics in the treatment of type 2 inflammatory diseases of the airway and skin will be detailed, along with strategies for the use of these agents in clinical practice. Case studies will be presented throughout the symposium, alongside insight from expert panel discussions to consolidate.
Chair: William Busse, United States
Welcome and Introduction
Speaker: William Busse, United States
Commonalities across Type 2 Inflammatory Diseases in Clinical Practice
Patient Cases Presented by:
Claus Bachert, Belgium
G.Walter Canonica, Italy
Stephan Weidinger, Germany
Discussion led by:
William Busse, United States
A Closer Look at the Pathophysiologic Mechanisms Driving Multiple Type 2 Inflammatory Diseases – All Faculty
Redefining the Management of Type 2 Inflammatory Diseases of the Airways and Skin – All Faculty
Closing Remarks and Panel Q&A – All Faculty
Speaker: William Busse, United States
| Satellite Symposium (SAT) DBV Technologies 17:45 – 19:15, Hall 10 |
 |
What are the clinical trial insights in peanut allergy with investigational EPIT?
Chair: Susanne Lau, Germany
Chair: Philippe Eigenmann, Switzerland
Leveraging the Immune Properties of the skin for an innovative approach to Food Allergy management
Speaker: Christophe Dupont, France
Adding a buffer to reduce the risk of reactions: Can efficacy meet peace of mind? (panel discussion)
Speaker: Katharina Blümchen, Germany
Speaker: André Knulst, Netherlands
Speaker: Benjamin Remington, Netherlands
| Satellite Symposium (SAT) CSL Behring 17:45 – 19:15, Hall 5 |
40 years of C1 inhibitor replacement therapy in the management of HAE
Learning objectives:
To highlight the 40 year legacy and history of C1 inhibitor replacement therapy and CSL Behring
To explain the mechanism of action of C1 inhibitor and the influence of C1 inhibitor replacement therapy in HAE
To describe the long-term safety and efficacy outcomes of C1 inhibitor replacement therapy using the recent data from the COMPACT open-label extension study
To detail outcomes of C1 inhibitor replacement therapy in pregnant, paediatric and geriatric patients
To emphasise the quality of life implications of HAE and how C1 inhibitor replacement therapy impacts these parameters
Chair: Konrad Bork, Germany
Chair: Werner Aberer, Austria
Patient video
Welcome and introduction
Speaker: Konrad Bork, Germany
C1 inhibitor in HAE and beyond
Speaker: Allen Kaplan, United States
Treatment outcomes in challenging patient groups with C1 inhibitor replacement therapy
Speaker: Timothy Craig, United States
C1 inhibitor replacement therapy: practical advice for patient management (RWE)
Speaker: Markus Magerl, Germany
Interactive panel discussion
Speaker: Werner Aberer, Austria
| Satellite Symposium (SAT) Purina Institute 17:45 – 19:15, Hall 4 |
Keep the cat, change the care pathway: a transformational approach to managing cat allergy
Learning objectives:
This symposium introduces an innovative approach to reducing environmental cat allergen levels while keeping the cat in the home. With proven efficacy in reducing symptoms in sensitized individuals, this solution will reframe one of the most difficult conversations you have with patients.
Chair: Antonella Muraro, Italy
A revolution in care pathways for cat allergy
Speaker: Jean Bousquet, France
A novel method of addressing human allergies to cats
Speaker: Ebenezer Satyaraj, United States
Speaker: H. James Wedner, United States
| Satellite Symposium (SAT) Medscape Education 17:45 – 19:15, Hall 9 |
Chair: Marc A. Riedl, United States
Welcome and Introduction
Speaker: Marc A. Riedl, United States
The Changing Treatment Landscape of HAE
Speaker: Marc A. Riedl, United States
From Reactive to Preventive Therape in HAE
Speaker: Marco Cicardi, Italy
New Treatment Approaches in HAE
Speaker: Aleena Banerji, United States
Living with HAE: Implications of the Patient – Panel discussion
Audience Q&A Session – All panel members
Program Close
Speaker: Marc A. Riedl, United States